Denosumab for the treatment of osteoporosis
Open Access
- 1 March 2017
- journal article
- review article
- Published by Elsevier in Osteoporosis and Sarcopenia
- Vol. 3 (1) , 8-17
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) TrialJournal of Bone and Mineral Research, 2012
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trialOsteoporosis International, 2012
- Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fracturesJournal of Bone and Mineral Research, 2011
- Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosisJournal of Bone and Mineral Research, 2011
- Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal womenOsteoporosis International, 2011
- Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?Osteoporosis International, 2011
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate CancerNew England Journal of Medicine, 2009
- Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast CancerJournal of Clinical Oncology, 2008
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trialBone, 2008